The Solution: eyemate®

eyemate® System

Our CE marked eyemate® presents a transformative innovation, which combines cutting edge medical technology with digital health solutions and enables improved therapy guidance and a more efficient disease management at glaucoma patients.

The eyemate® system consists of a permanent implantable and biocompatible micro sensor, responsible for intraocular pressure measurements. Since glaucoma is a chronic disease which needs to be monitored and managed for the rest of the life of a patient, it is crucial that the micro sensor is long-term durable. The micro sensor is powered by an external hand-held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage..
The operation of this patient hand-held device is extremely simple and uncomplicated for the patient. In the future, the data will be transmitted via a wireless data connection to a secure internet-based database by means of a GSM module on the hand-held device.The eye doctor will access this data base in order to get information about the disease status of the patient. And he can define events to attain an automated alert, in case these events are detected by the eyemate® system. A smartphone app will be made available, which allows the patient to view the pressure profile and to track the pressure history. The app can also be used to communicate with the doctor. And a medication schedule can be established in this app, that reminds the patient automatically when he has to  apply his glaucoma medication.
eyemate®-IO, intraocular micro sensor for intraocular pressure measurement in patients with primary open-angle glaucoma

In the completed ARGOS-02 clinical trial, the micro sensor was implanted as part of an ongoing cataract surgery. Approximately 15% of patients undergoing cataract surgery (currently in Germany about 800,000 per year)* are at the same time suffering from glaucoma and are thus possible candidates for this product. Co-implantation of the CE-approved eyemate® sensor in cataract surgery is easy from a surgical point of view and does neither require significant additional time for surgery nor significantly increase patient risk.

*Quellen: Bundesverband der Augenärzte [ Link1 | Link2 ]

eyemate®-IO, intraocular micro sensor for intraocular pressure measurement at keratoprosthesis patients
As part of the completed ARGOS-KP01 study, the eyemate®-IO sensor was tested at keratoprosthesis patients. Up to 75% of patients who receive a corneal prosthesis suffer from increased intraocular pressure (secondary glaucoma), resulting in post-operative complications for these patients, to the fatal consequence of very rapid blindness. Conventional methods of intraocular pressure measurement do not work in these patients. Therefore, a tight pressure monitoring to detect pressure crises is of enormous importance. The implantation of the CE-approved eyemate®-IO sensor is carried out as part of the already performed keratoprosthesis operation. Thus, the intraocular pressure can be monitored well from the first day on and therapy can be adjusted immediately in order to avoid dangerous pressure increases.

*Quelle: [ Link ]

eyemate®-SC, extraocular micro sensor for intraocular pressure measurement in patients with primary and secondary forms of glaucoma

There are a considerable number of patients in whom intraocular placement of the eyemate®-IO is not possible. Especially in still "phakic" glaucoma patients, where no cataract surgery has been done or is indicated. These patients still have their human lens, which is why, for physiological reasons, it is not possible to place the micro sensor intraocularly. There is also the subsegment of narrow-angle glaucoma patients, where the use of the eyemate®-IO is not feasible. Placement of the eyemate®-IO in those eyes is not recommended, as anatomical reasons may exacerbate the intraocular pressure problem. Implandata and its medical consultants are therefore following the extra-ocular placement strategy of the micro sensor named in the study ARGOS-SC. The sensor is minimally invasively placed under the sclera of the eye and can remain there permanently without any impairment of the patient. Initially, the ARGOS-SC is implanted in combination with glaucoma surgical interventions, such as non-penetrating glaucoma surgery, which are required in any case. In the long term, however, due to very careful surgical techniques, it will be possible to place the ARGOS-SC at a very early stage of glaucoma, independently of other surgical interventions. Also in glaucoma patients applies: the earlier the disease surveillance is started, the higher the chance of avoiding consequential damage, such as gradual loss of vision or even blindness. Currently, the ARGOS-SC micro sensor is undergoing clinical trials. The results obtained so far are so promising that CE certification can be expected shortly.
More detailed information under: